EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Rezera Announces Late-Breaking Presentation of RESOLVE-1 Clinical Data at the American Heart Association (AHA) Scientific Sessions 2026
Boston, MA, September 23, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Rezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in